Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | TDP2 | O95551 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762865 | 0.85 | MAPT (0.57) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL2763675 | 0.81 | AKT1 (0.45) | SMN1; SMN2ALDH1A1PKMLMNAHSD17B10 | |
| SCHEMBL2762559 | 0.80 | PTPN1 (0.43) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2762411 | 0.78 | MAPT (0.62) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL2762933 | 0.77 | MAPT (0.59) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL2762879 | 0.76 | MAPT (0.58) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL2763423 | 0.76 | MAPT (0.59) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL2762860 | 0.75 | MAPT (0.56) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL2762669 | 0.75 | MAPT (0.56) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 | |
| SCHEMBL2762753 | 0.75 | MAPT (0.58) | MAPTSMN1; SMN2TP53ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | claimed |
| WO-2004112783-A1 | NEW USE IV | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | claimed |
| EP-1283832-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | claimed |
| WO-2001090092-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | claimed |
| EP-1283832-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-10-20 | — | — | EP | disclosed |
| US-7132436-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-11-07 | — | — | US | disclosed |
| WO-2004112783-A1 | NEW USE IV | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | CLARIO TECH LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-1283832-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090092-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166689-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | MAPT 3275/4885SMN1; SMN2 3295/4885TP53 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.